(Breast Cancer) Is Enhertu Effective for Brain Metastases?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
Enhertu in HER2-Positive Breast Cancer with Brain Metastases — TUXEDO-1 Trial
On August 8, 2022, Rupert Bartsch and colleagues at the Medical University of Vienna published in the medical journal Nature Medicine the efficacy and safety results of the TUXEDO-1 Phase 2 trial evaluating Enhertu (trastuzumab deruxtecan) in patients with HER2-positive breast cancer with brain metastases.
Trial Design
The TUXEDO-1 Phase 2 trial administered Enhertu (5.4 mg/kg, 3-week cycles) to 15 patients with HER2-positive breast cancer with brain metastases who had either received no prior treatment or had prior treatment. The primary endpoint was intracranial response rate.
Patient characteristics: 60% of patients had developed brain metastases during disease progression on prior treatment; 14 female and 1 male patient; median age 69 years (range 30–76); ECOG performance status 0 in 40%; 12 patients had hormone receptor-positive disease.
Efficacy Results
- Intracranial response rate (primary endpoint): 73.3% (N=11/15)
- Complete response: 13.3% (N=2)
- Partial response: 60% (N=9)
- Stable disease: 20% (N=3)
- Median progression-free survival: 14 months
Conclusions
Based on the TUXEDO-1 trial results, Rupert Bartsch and colleagues concluded that Enhertu demonstrated a high intracranial response rate in patients with HER2-positive breast cancer with brain metastases.
Source: https://www.nature.com/articles/s41591-022-01935-8
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4